← Human Trials & Peer-Reviewed Studies
Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Plain-language guide to PMID 31703120 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 1312 adults.
Key Facts
- PMID
- 31703120
- Journal
- JAMA
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- de Boer IH et al. (12 authors)
- DOI
- 10.1001/jama.2019.17380
- Registered trial
- NCT01684722
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Who Took Part
The study group was 1312 adults.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Randomized clinical trial with a 2 × 2 factorial design conducted among 1312 adults with type 2 diabetes recruited between November 2011 and March 2014 from all 50 US states as an ancillary study to the Vitamin D and Omega-3 Trial (VITAL), coordinated by a single center in Massachusetts.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Follow-up was completed in December 2017.
What Was Measured
The subject headings attached to it are Cholecalciferol, Diabetes Mellitus, Type 2, Disease Progression, Docosahexaenoic Acids, Eicosapentaenoic Acid, Fatty Acids, Omega-3 and Gastrointestinal Hemorrhage.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 1312 adults.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (JAMA), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.